23andMe

Investment Highlights

Company Overview

The company offers information and tools for individuals to learn about and explore their DNA.

Enabling individuals to discover ancestral origins and trace the lineage with a personalized analysis of DNA.

The company uses Illumina HumanOmniExpress-24 format chip that comprises a custom panel of probes for detecting genetic variations.

Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits.

The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate.

The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases.

The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas.

Find out what your DNA says about you and your family

See how your DNA breaks out across 2000+ regions worldwide

Discover DNA relatives from around the world

Share reports with family and friends

Learn how your DNA influences your facial features, taste, smell and other traits

Financials

Enterprise Value US$2.51B

Stock Information

PrimaryMarkets has sellers of this Unicorn Stock.

Minimum traction size – US$250,000.

All buyers must be Sophisticated/Accredited/Wholesale/Institutional Investors.

If interested please contact trade@primarymarets.com.

Team